ArticleJournal of clinical medicine2019

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.

Eugeni Lopez-Bonet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.